Open main menu
Home
Random
Donate
Recent changes
Special pages
Community portal
Preferences
About Stockhub
Disclaimers
Search
User menu
Talk
Contributions
Create account
Log in
Editing
Pfizer Inc.
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
==== Main Products (Key Revenue-Generating Products) ==== Pfizer's flagship products stand as vanguards of medical innovation, diligently sculpted to make indelible marks on health and well-being. The main products of the company in terms of revenues are Comirnaty, Paxlovid, Elliquis, Prevnar family, Ibrance, Vyndagel family, Xeljanz, Xtandi, and Inlyta. '''Comirnaty:''' An mRNA-based COVID-19 vaccine developed in partnership with BioNTech, designed to champion the fight against the pandemic. Both companies share the developmental endeavor's financial burden. '''Paxlovid:''' A prescription beacon of hope, specifically tailored to combat moderate COVID-19 manifestations in high-risk adults, strategically poised to curtail progression to severe stages. '''Elliquis:''' A groundbreaking Novel Oral Anticoagulant birthed in collaboration with Bristol Myers Squibb, engineered to provide an alternative to the traditional warfarin treatment. '''Prevnar:''' A lineage of pneumococcal vaccines championing the protection of individuals across generations against the perils of Streptococcus pneumoniae infections. '''Ibrance:''' A pharmaceutical masterpiece, poised to address the relentless progression of HR+, HER2- breast cancer as it metastasizes to distant domains within the body. '''Vyndaqel:''' A remarkable entity set to battle the rare affliction known as transthyretin amyloidosis, ushering in hope and healing for those ensnared by this ailment. '''Xtandi:''' A trailblazing androgen receptor inhibitor, carefully devised to impede the androgen receptor pathway's aberrant steps within tumor cells, an achievement borne from collaboration with Astellas. '''Inlyta:''' A strategic intervention meticulously designed to stunt tumor growth by attenuating the blood supply, forging a potent weapon against cancer's insidious advance. The revenue contribution as of December 2022 can be seen in the table below: {| class="wikitable" |+ !Product !Revenues !% of Total Revenues |- |Comirnaty |$37,806 |37.68% |- | Paxlovid | $18,933 |18.87% |- |Eliquis | $6,480 | 6.46% |- |Prevnar family |$6,337 |6.31% |- |Ibrance |$5,120 |5.1% |- |Vyndagel family | $2,447 | 2.44% |- |Xeljanz |$1,796 |1.79% |- |Inlyta | $1,003 |0.01% |}Comirnaty and Paxlovid together accounted for 57% of 2022 total revenues, which shows a high concentration level in the company's revenue stream. Revenue generation of these two products is not expected to be at similar levels moving forward since the pandemic is coming to an end.
Summary:
Please note that all contributions to Stockhub may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
Stockhub:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)